Issue 12, 2015

Synthesis and biological evaluation of piperazine group-linked bivalent β-carbolines as potential antitumor agents

Abstract

A series of novel bivalent β-carbolines with a piperazine group spacer between 3-methylene units were synthesized and evaluated as antitumor agents. The results demonstrated that compounds 7e and 7g exhibited the most potent cytotoxic activities against ten tumor cell lines. Structure–activity relationships analysis indicated that (1) the substituents in positions 1 and 9 of the β-carboline ring played a significant role in modulating the antitumor activity; (2) the introduction of alkyl groups into position-9 of the β-carboline nucleus enhanced their cytotoxic potencies and the butyl substituent was the optimal group. Investigation of the preliminary mechanism of action demonstrated that compound 7g showed obvious anti-angiogenic activity in the in vivo CAM assay, and the potency was similar to that of CA4P (200 μM).

Graphical abstract: Synthesis and biological evaluation of piperazine group-linked bivalent β-carbolines as potential antitumor agents

Supplementary files

Article information

Article type
Concise Article
Submitted
25 Jul 2015
Accepted
21 Oct 2015
First published
03 Nov 2015

Med. Chem. Commun., 2015,6, 2170-2174

Author version available

Synthesis and biological evaluation of piperazine group-linked bivalent β-carbolines as potential antitumor agents

R. Sun, R. Liu, C. Zhou, Z. Ren, L. Guo, Q. Ma, W. Fan, L. Qiu, H. Yu, G. Shao and R. Cao, Med. Chem. Commun., 2015, 6, 2170 DOI: 10.1039/C5MD00312A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements